| Name | Title | Contact Details |
|---|---|---|
Paul Wille |
Director Of Product Development | Profile |
Ashley Jones |
Human Resources Director | Profile |
Kristina Maximenko |
Head of Human Resource | Profile |
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
biomarkerinc is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.
NOVOS develops science-based solutions to slow down human aging. NOVOS is a Public Benefit Corporation devoted to improving human longevity & health.